A team led by scientists at the Case Western Reserve University School of Medicine has identified a new therapeutic approach for combating neurodegenerative diseases.
Rutgers study led by undergrads and gap-year students breaks ground in the field of neuroscience and suggests experimental medication could treat dementia.
The Dementia Care (D-CARE) Study (2019-2023), which was conducted at four clinical trial sites in the U.S., compared three approaches in dementia care. Despite challenges during the COVID-19 pandemic, D-CARE successfully enrolled 2,176 racially/ethnically diverse persons with Alzheimer’s disease or related dementias and their caregivers.
Irvine, Calif., Feb. 14, 2024 — A research team led by the University of California, Irvine has created 20 new recombinant rabies viral vectors for neural circuit mapping that offer a range of significant advantages over existing tools, including the ability to detect microstructural changes in models of aging and Alzheimer’s disease brain neurons.
In an effort five years in the making, UNC School of Medicine cell biologist Sarah Cohen, PhD, and Rockefeller University’s Ian Windham, PhD, describe the interplay between fats and proteins in brain cells and how their dysfunction contributes to the development of late-onset Alzheimer’s disease.
Beckman researchers and collaborators received $3 million from the U.S. National Institute on Aging to develop diagnostic tools and imaging agents for the early detection of Alzheimer’s disease.
Claudia Padilla, MD, at Baylor Scott & White Health, discusses Alzheimer’s and a new treatment. What You Need to Know: Alzheimer’s disease is a type of dementia. The most common sign is short-term memory loss. New medication targets the protein…
University at Albany scientist Scott Tenenbaum, founder of UAlbany spinoff company sxRNA Technologies, Inc. (sxRNA Tech), has received $500,000 from the National Institute on Aging, part of the National Institutes of Health, to study how aging brain cells shape the progression of Alzheimer’s disease, and advance RNA technology that could inform new therapeutics to prevent and treat Alzheimer’s and related dementias.
RUDN University chemists have obtained new azaheterocyclic compounds that inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), regulators of the central nervous system.
Compared to urban dwellers, racially/ethnically diverse older adults face up to an 80 percent greater risk of cognitive impairment in older age, and 2.5 times potentially preventable Alzheimer’s-related (ADRD) hospitalizations.
Nerve cells in the brain demand an enormous amount of energy to survive and maintain their connections for communicating with other nerve cells.
Commonly used vaccines may also protect against dementia, according to a recent paper published in the Journal of Alzheimer’s Disease [J. Alzheimer’s Disease 2023; 95(2): 703–718)]. The authors found that after receiving the tetanus/diphtheria vaccine and whooping cough (aka, pertussis)…
November is National Alzheimer’s Disease Month Hackensack Meridian Hackensack University Medical Center and the hospital’s Center for Memory Loss and Brain Health are conducting research for Alzheimer’s Disease through four clinical trials with the goal of addressing and improving the…
Researchers at Indiana University School of Medicine will play key roles in a national consortium led by Wake Forest University School of Medicine to study the use, interpretation and implementation of biomarkers to diagnose Alzheimer’s disease. The multi-institution effort is funded by a five-year, $9 million grant from the National Institute on Aging, part of the National Institutes of Health, that will establish the Alzheimer’s Diagnosis in Older Adults with Chronic Conditions (ADACC) Network.
Fueled by new five-year funding expected to total $81 million from the NIH’s National Institute on Aging, a multi-institution team will work to improve understanding of the health care workforce that cares for people with dementia, through surveys and other methods that will produce data for clinicians, researchers, policymakers and others to use.
The Resource Center for Alzheimer’s and Dementia Research in Asian and Pacific Americans will work to advance behavioral, social and economic research related to Alzheimer’s disease and other dementias especially in older Asian and Pacific Americans.
Led by scientists at UNC-Chapel Hill and UC-San Francisco, research reveals new non-coding genetic variants associated with Alzheimer’s disease functioning in microglia – brain cells already implicated in the progression of this often-fatal neurodegenerative condition.
Since 2012, September has been celebrated as World Alzheimer’s Month. Back then, and only eleven years ago, an average of 2 out of 3 people had little understanding of Alzheimer’s disease and associated dementias.
The three-year, $1.3 million grant from the Administration for Community Living’s Alzheimer’s Disease Program Initiative will support a groundbreaking project designed to advance health equity and improve quality of life for individuals living with or at high risk for Alzheimer’s disease and related dementias and their family caregivers.
A recent study shows that a protein called ABCA7 plays a functional role as a potential biological link between cholesterol and inflammation in Alzheimer’s disease. The new work was published online August 25 in the journal Cells.
A $750,000 philanthropic grant from the Carl Angus DeSantis Foundation will help FAU develop partnerships and programs that will establish best practice for coordinated care and research for Alzheimer’s disease and related dementias.
Scientists at St. Jude Children’s Research Hospital found that a subset of CD8+ T cells in the brain lessens the activation of microglia and limits disease pathology in a model of Alzheimer’s disease.
Neuroscience researchers at Wayne State University published a review article that confirms the usefulness of neurofilament light (NfL) blood levels to predict the likelihood and rate of progression of neurodegeneration in Alzheimer’s disease.
Lake Okeechobee rural residents are subjected to repeated, intermittent exposures to air pollution during agricultural fires.
A new study by Indiana University School of Medicine researchers uses more genetically diverse mouse models to study the accumulation and spread of abnormal tau protein deposits in the brain.
New results from researchers at UC San Diego School of Medicine suggest that intermittent fasting could be an effective treatment approach for Alzheimer’s disease.
Prior vaccination against tetanus and diphtheria, with or without pertussis (Tdap/Td); herpes zoster (HZ), better known as shingles; and pneumococcus are all associated with a reduced risk for developing Alzheimer’s disease, according to new research from UTHealth Houston.
Promising preclinical results from UC San Diego show hematopoietic stem cell therapy was effective in rescuing memory loss, neuroinflammation and beta amyloid build-up in a mouse model of Alzheimer’s disease.
A growing body of evidence suggests extra virgin olive oil can help prevent cognitive decline due to Alzheimer’s disease. In a new study, Yale School of Medicine researchers led by Natalie Neumann, MD, trained a machine learning algorithm on current…
By analyzing data from nearly 13,000 subjects who participated in a long-term aging study, Florida State University researchers found that an interviewer’s rating of a cognitively healthy person’s memory successfully predicted the likelihood of developing dementia over a 15-year period.
A new study lends further weight to the idea that vision problems and dementia are linked. In a sample of nearly 3,000 older adults who took vision tests and cognitive tests during home visits, the risk of dementia was much higher among those with eyesight problems – including those who weren’t able to see well even when they were wearing their usual eyeglasses or contact lenses.
New Alzheimer’s research from UVA Health suggests that enhanced light sensitivity may contribute to “sundowning” – the worsening of symptoms late in the day – and spur sleep disruptions thought to contribute to the disease’s progression.
New therapies for early Alzheimer’s disease, monoclonal antibodies that remove amyloid-β plaques in the brain, are bringing hope to people whose lives have been affected by the disease. To help neurologists discuss these therapies with patients and caregivers, the American Academy of Neurology has developed an Emerging Issues in Neurology article, published online on July 26, 2023, in Neurology®, the medical journal of the American Academy of Neurology.
Kundalini yoga, a form of yoga that focuses on breathing, meditation, and mental visualization, appeared beneficial for older women who had risk factors for Alzheimer’s disease and concerns about episodes of memory decline, according to a UCLA Health study.
A recent study has used Artificial Intelligence (AI) to reveal the remarkable potential of extra virgin olive oil (EVOO) in the fight against Alzheimer’s disease (AD). Researchers combined AI technology, chemistry, and omics research to identify specific bioactive compounds in EVOO that show promising effects in treating and preventing AD.
A new study by researchers at Case Western Reserve University revealed that the progression of Alzheimer’s disease (AD) can be slowed by suppressing a specific protein in the brain that causes corrosion.
A new study suggests that incorporating olive oil into your diet could help reduce the risk of dying from dementia.
The majority of older adults with cognitive impairment are still driving, despite concerns raised by caregivers and others, a study finds. Researchers say it’s best for caregivers to start conversations surrounding driving earlier while the care recipient is able to understand and actively participate in the discussion.
Parkinson’s disease, another neurodegenerative process, produces in patients a unique smell, which trained dogs can detect. Alzheimer’s disease, the leading dementia, needs to be similarly studied. This $200,000 challenge award is posted to help stimulate this necessary research.
Liana Apostolova, MD is the associate dean of Alzheimer’s disease research at Indiana University School of Medicine. Dr. Apostolova and others presented results of the phase 3 clinical trial of Donanemab at the Alzheimer’s Association International Conference. The study, also published…
Press materials are now available for NUTRITION 2023, the annual flagship meeting of the American Society for Nutrition (ASN).
The neurons in our bodies are dotted with tiny pores that let essential molecules pass in and out of our cells. Neurons need these channels to send the signals that allow us to move, think, and perceive the world around us. Now, structural biologists at Cold Spring Harbor Laboratory (CSHL) have captured never-before-seen images of one of the largest pores in human neurons.
Study represents a major milestone toward health equity for underrepresented populations in Alzheimer’s disease research
Researchers at Washington University School of Medicine in St. Louis and Lund University in Sweden have discovered an Alzheimer’s biomarker in the cerebrospinal fluid known as MTBR-tau243 can be used to track the progression of disease and could speed drug development.
Because amyloidosis doesn’t affect a specific organ and can be present throughout the body including the heart, kidneys, liver and brain, unraveling the underlying cause of amyloid fibril creation – a hallmark of this disease – is complex and challenging. A monumental $11.5 million gift from philanthropists Ann and John Wood will enable FAU’s Schmidt College of Medicine to create a game-changing infrastructure using a whole-body approach and multi-disciplinary team.
Age-related cognitive decline and the escalating prevalence of Alzheimer’s disease are pressing social challenges as the population of those 65 and older continues to expand. Age is the primary risk factor, but research has shown that social and structural determinants of health play significant roles in the higher incidence of Alzheimer’s among marginalized communities.
On July 6, the U.S. Food and Drug Administration granted full approval to the new Alzheimer’s disease drug lecanemab (brand name Leqembi). The medication was granted accelerated approval in January. With the landmark decision, University of Michigan Health, Michigan Medicine,…
The FDA has granted Priority Review to the anti-Alzheimer’s drug Leqembi for the traditional approval application, with required action from the agency by July 6, 2023. Paul E. Schulz, MD, professor of neurology and director of the Neurocognitive Disorders Center with McGovern…
The U.S. Food and Drug Administration is considering full approval of the new Alzheimer’s disease drug Lecanemab (brand name Leqembi), with a decision expected by July 6. University of Michigan Health, Michigan Medicine, has an expert available to talk about…
The University of California, Irvine has received a five-year, $10 million grant from the National Institutes of Health to lead a multi-institutional study of specific brain cell vulnerabilities to abnormal tau protein deposits in regions affected in the early stages of Alzheimer’s disease.